Catal­ent amps up plans to man­u­fac­ture J&J's Covid-19 vac­cine, adding vial fill­ing line in Italy

A lit­tle more than a year af­ter Catal­ent CEO John Chimin­s­ki ac­quired Bris­tol My­ers Squibb’s man­u­fac­tur­ing fa­cil­i­ty in Anag­ni, Italy, the big CD­MO is us­ing it to amp up sup­plies of J&J’s Covid-19 vac­cine.

On Wednes­day the phar­ma gi­ant an­nounced an ex­pand­ed deal to lay on added man­u­fac­tur­ing ca­pac­i­ty in­volv­ing vial-fill­ing, in­spec­tion, la­bel­ing, and pack­ag­ing ser­vices. Catal­ent plans to scale up a new, high speed vial fill­ing line to in­crease pro­duc­tion for J&J’s one-shot vac­cine, which re­cent­ly won a ma­jor OK in the US. The sprawl­ing plant en­com­pass­es 300,000 square feet of space.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER